Table 1.
Characteristics of COVID-19 Trials That Include Children Identified in ClinicalTrials.gov
| A. Summary | |
|---|---|
| COVID-19 phase 1–3 trials identified | 1687 |
| Trials allowing inclusion of children | 96 (6%)* |
| B. Pediatric populations in trials allowing inclusion of children | |
| Adult trials allowing inclusion of children | 89 (93%) |
| Eligibility at unspecified age | 31 (35%) |
| Eligibility below 1 y of age | 2 (2%) |
| Eligibility between 1 and 10 y of age | 10 (11%) |
| Eligibility between 10 and 14 y of age | 19 (21%) |
| Eligibility above 15 y of age | 27 (30%) |
| Pediatric trials (only children included) | 7 (7%) |
| C. Products being evaluated† | 162 |
| Products with anticipated antiviral activity | 94 (58%) |
| New anti-infectives | 36 (38%) |
| Remdesivir | 10 (11%) |
| Chloroquine, hydroxychloroquine | 11 (12%) |
| Monoclonal antibodies | 15 (16%) |
| Repurposed anti-infectives | 46 (49%) |
| Antibiotics | 9 (10%) |
| Antiparasitic drugs | 15 (16%) |
| Antiretrovirals | 6 (6%) |
| Antivirals | 16 (17%) |
| Herbal medicines and vitamin supplements | 12 (13%) |
| Products with anticipated anti-inflammatory and/or anti-ARDS activity | 60 (37%) |
| Monoclonal antibodies | 12 (20%) |
| Corticosteroids | 6 (10%) |
| Other anti-inflammatory products | 12 (20%) |
| T-cell or stem cell infusions | 8 (13%) |
| Convalescent plasma/immunoglobulins | 19 (32%) |
| Anticoagulants | 3 (5%) |
| Products with anticipated prevention utility | 8 (5%) |
| Vitamin D, A or B | 5, 2, 1 (63%, 25%, 13%) |
Data as of 20 June 2021.
*Among the 96 trials open to enrollment for children, 43% are planning to recruit up to 100 participants only.
†Twenty-nine (30%) of the trials listed evaluated >1 product.
ARDS, acute respiratory distress syndrome.